Nitika Arora Gupta

Nitika Arora Gupta

Auto-generated profile, based on publicly available information

Nitika Arora Gupta

Children's Healthcare of Atlanta and Emory University School of Medicine Atlanta Georgia USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2020 in Hepatology
Verified
Journal Article
Closed access
PDF file
SFSandy Feng
Sandy Feng
JBJohn C. Bucuvalas
John C. Bucuvalas
GMGeorge V. Mazariegos
George V. Mazariegos
JMJohn C. Magee
John C. Magee
ASAlberto Sanchez‐Fueyo
Alberto Sanchez‐Fueyo
ADAnthony J. Demetris
Anthony J. Demetris

19 December 2020 in Hepatology
Verified
Journal Article
Closed access
MDMark R. Deneau
Mark R. Deneau
CMCara Mack
Cara Mack
EPEmily R. Perito
Emily R. Perito
ARAmanda Ricciuto
Amanda Ricciuto
PVPamela L. Valentino
Pamela L. Valentino
SGStephen L. Guthery
Stephen L. Guthery

14 May 2021 in Apoptosis
Verified
Journal Article
Closed access
PDF file
VKVasantha L. Kolachala
Vasantha L. Kolachala
CLChrissy Lopez
Chrissy Lopez
MSMing Shen
Ming Shen
DSDmitry Shayakhmetov
Dmitry Shayakhmetov
NGNitika Arora Gupta
Nitika Arora Gupta

6 January 2022 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
JBJulia M. Boster
Julia M. Boster
RSRiccardo Superina
Riccardo Superina
GMGeorge V. Mazariegos
George V. Mazariegos
GTGregory M. Tiao
Gregory M. Tiao
JRJonathan P. Roach
Jonathan P. Roach
SSShikha S. Sundaram
Shikha S. Sundaram
Management of unresectable pediatric hepatoblastoma (HB) and hepatocellular carcinoma (HCC) remains challenging. The Society of Pediatric Liver Transplantation (SPLIT) database was used to study survival predictors in pediatric liver transplantation (LT) for HB and HCC. Event-free survival (EFS), associated risk factors, and post-operative complications were studied in children requiring LT for HB/HCC at 16 SPLIT centers. Three-year EFS was 81% for HB (n=157) and 62% for HCC (n=18) transplants. Of HB transplants, 6.9% were PRETEXT II and 15.3% were POST-TEXT I/II. Tumor extent did not impact survival (p=NS). Salvage (n=13) and primary HB transplants had similar 3-year EFS (62% versus 78%, p=NS). Among HCC transplants, 3-year EFS was poorer in older patients (38% in ≥8-year-olds vs 86% <8-year-olds), larger tumors (48% for those beyond versus 83% within Milan criteria, p=NS). Risk of infection (HR 1.5, 95%CI 1.1-2.2, p=0.02) and renal injury (HR 2.4, 95%CI 1.7-3.3, p<0.001) were higher in malignant versus non-malignant LT. Survival is favorable for pediatric HB and HCC LT, including outcomes after salvage transplant. Unexpected numbers of LTs occurred in PRE/POST-TEXT I/II tumors. Judicious patient selection is critical to distinguish tumors that are potentially resectable; simultaneously, we must advocate for patients with unresectable malignancies to receive organs.


25 February 2019 in Liver International
Verified
Journal Article
Closed access
PDF file
SPSirish K. Palle
Sirish K. Palle
KNKushal B. Naik
Kushal B. Naik
CMCourtney E. McCracken
Courtney E. McCracken
VKVasantha L. Kolachala
Vasantha L. Kolachala
RRRene Romero
Rene Romero
NGNitika A. Gupta
Nitika A. Gupta